Swiss Pharma Industry Calls for Policy Changes Following US MFN Pricing Impact Survey

A survey by Interpharma, the association of research-based pharmaceutical companies in Switzerland, reports that seven of 22 new innovative medicines were not submitted for reimbursement in Switzerland between January 2025 and June 2026, with member companies attributing these decisions to the US most-favored-nation drug pricing policy.

The Baseline

• An Interpharma survey found that seven of 22 new innovative medicines were not submitted for reimbursement in Switzerland between January 2025 and June 2026.
• According to Interpharma, member companies linked these decisions to the US most-favored-nation drug pricing policy and its potential impact on US prices.
• Interpharma is calling for changes to Swiss reimbursement policy to account for the potential interaction with US drug pricing reforms.

Interpharma has published new survey findings examining how the US most-favored-nation (MFN) drug pricing policy is affecting decisions to launch and seek reimbursement for innovative medicines in Switzerland. Based on responses from its member companies, the Swiss pharmaceutical industry association reports that the policy is already influencing submission decisions, prompting renewed calls for changes to the country’s pricing and reimbursement framework.

The survey examined 22 new innovative medicines considered for submission in Switzerland between January 2025 and June 2026. Of these, seven were not submitted for inclusion on Switzerland’s Specialties List, three of which were also not submitted to Swissmedic for regulatory approval. The findings come from an anonymized and aggregated survey of Interpharma members examining submission decisions over the 18-month period.

Under the MFN approach, Switzerland is among the countries used as a reference for US drug pricing. According to Interpharma, the survey indicates that member companies are delaying or foregoing the launch of some new therapies in Switzerland to avoid affecting their prices in the US.

Interpharma said the survey indicates that the effects of the MFN regime are “already measurable.” The organization also noted that Switzerland has comparatively low purchasing-power-adjusted prices for innovative medicines and is among the countries referenced under the US approach.

In Switzerland, medicines generally need to be included on the Federal Office of Public Health’s Specialties List to be reimbursed through compulsory health insurance. Medicines that are not submitted for inclusion are therefore not routinely available through this reimbursement route. The survey follows previous analysis of the availability of new therapies in Switzerland. Interpharma cited a study using data from 2021 to 2024 which found that, compared with Germany, only about half of new therapies were available to patients in Switzerland through the Specialties List.

Interpharma has also commented on proposed revisions to Switzerland’s Health Insurance Ordinance and Health Insurance Benefits Ordinance. The organization argues that the proposals place a strong emphasis on costs and do not sufficiently account for the potential interaction between Swiss reimbursement policy and the US MFN approach. It has called for the proposals to be revised and for Switzerland to develop what it describes as an “MFN-compatible pricing system” that considers access to care, quality, and the costs associated with pharmaceutical innovation.